DOCSLIB.ORG

Intralipid-A Magic Bullet?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Intralipid-A Magic Bullet? Intralipid-A Magic Bullet? *Corresponding author: Joseph Eldor Theoretical Medicine Institute, Jerusalem, Israel Email: Published By: MedCrave Group LLC September 15, 2017 Table of Contents Chapter 1: Intralipid-Iodine for Hysterosalpingography in Infertile Women 1 1. Abstract 2 2. Introduction 3 3. Conclusion 5 4. References 6 Chapter 2: Intralipid Treatment for Post Operative Delirium 7 1. Abstract 8 2. Keywords 8 3. Post Operative Delirium 9 4. Conclusion 12 5. References 13 Chapter 3: Can Intralipid Infusion Open A Coronary Occlusion Causing Acute Myocardial Infarction? 14 1. Abstract 15 2. Keywords 15 3. Introduction 16 4. Conclusion 20 5. References 21 Chapter 4: Intralipid Treatment for Alzheimer Disease 22 1. Abstract 23 2. Keywords 23 3. Dr. Aloysius "Alois" Alzheimer 24 4. Blood-Brain Barrier 30 5. Conclusion 33 6. References 34 Chapter 5: Intralipid Treatment for Newborns with Meconium Stained Amniotic Fluid (MSAF) 36 1. Abstract 37 2. Keywords 37 3. MAS and MSAF 38 4. Endotracheal Suction 38 5. Conclusion 42 6. References 43 Chapter 6: Warburg Effect and Intralipid Effect on the Mitochondria of Cancer Cells 44 1. Abstract 45 2. Keywords 45 3. Dr. Otto heinrich Warburg 46 4. Mitochondria In Cancer Cells 46 5. Intralipid 48 6. Conclusion 52 7. References 53 Chapter 7: Combined Intralipid - Urotherapy for Patients with Cancer (Part 1, Part 2, Part 3) 57 Part 1 57 1. Abstract 58 2. Keywords 58 3. The Philosophy of Cancer 59 4. Immunotherapy 60 5. Preconclusion 61 6. Conclusion No.1 62 7. References 62 Part 2 65 1. Cancer Antigens 65 2. Cancer Vaccines 67 3. Cancer Immunotherapy 69 4. Cancer Antibodies 74 5. Conclusion No. 2 76 6. References 77 Part 3 79 1. Intralipid Effects on the Immune System 79 2. Conclusion No. 3 81 3. References 82 Chapter 8: Combined Spinal Epidural Catheters for Epidural Cooling, Cerebrospinal Fluid Aspiration and Spinal 83 Intralipid Infusion for Treatment of Spinal and Brain Injuries, Diseases and Protection 1. Abstract 84 2. Keywords 84 3. Introduction 85 4. CSF Role in Ischemic Injury 85 5. Traumatic Injury to the Central Nervous System 85 6. Inadvertent Intralipid Spinal-Epidural Injection 86 7. Epidural Saline Infusion 87 8. Paraplegia-A Serious Complication of Descending and Thoraco-Abdominal Aortic Operations 87 9. Hypothermia for Prevention of Paraplegia Associated with Thoracic Aortic Surgery 88 10. Epidural Cooling Catheter to Protect the Spinal Cord from Ischemia during Aortic Surgery 88 11. The Effect of Intrathecal Tetracaine on the Neurological Sequelae of Spinal Cord Ischemia and 90 Reperfusion with Aortic Occlusion 12. The Use of Prophylactic Hypothermia for Traumatic Brain Injury 90 13. Lipid Neuroprotection 91 14. Lipid Resuscitation Therapy 92 15. Pretreatment or Resuscitation with a Lipid Infusion 93 16. Intralipid Reversing other Drugs Toxicity 93 17. The Lipid Sink Effect 94 18. Guidelines for the Management of Local Anaesthetic Toxicity 95 19. Lipid Emulsion Overdose 95 20. Intralipid Rescue: 1966-2009 95 21. Intralipid Prevents and Rescues Fatal Pulmonary Arterial Hypertension and Right Ventricular Failure 96 and Enhances the Inflammatory Response to Endotoxin 22. Is Intralipid Approved by the FDA for Local Anesthesia-Induced Cardiovascular Collapse or 96 Resuscitation? 23. Conclusions 97 24. References 98 Chapter 9: Intralipid Treatment: Is It Only The Tip Of An Iceberg? A New Suggestion: Bone Cement Implantation 100 Syndrome (BCIS) 1. Abstract 101 2. Keywords 101 3. Pretreatment or Resuscitation with a Lipid Infusion 102 4. Intralipid rescue: 1966-2009 104 5. Bone Cement Implantation Syndrome (BCIS) 105 6. Conclusion 107 7. References 107 Chapter 10: Intralipid for Amniotic Fluid Embolism (AFE)? 108 1. Abstract 109 2. Introduction 110 3. Material and Method 110 4. Statistical Analysis 110 5. Results 112 6. Discussion 112 7. Conclusion 113 8. References 113 Chapter 11: Intralipid-Iodine for Imaging 115 1. Field of the Invention 116 2. Summary of the Invention 116 3. Detailed Description of the Invention 116 4. Conclusion 119 5. References 119 Chapter 12: Intralipid use in Trauma 120 1. Abstract 121 2. Keywords 121 3. Introduction 122 4. Intralipid Use In Rapid Blood Loss 122 5. Conclusion 125 6. References 125 Intralipid-A Magic Bullet? Chapter I Intralipid-Iodine for Hysterosalpingography in Infertile Women 1 Intralipid-A Magic Bullet? Abstract Tubal disease is the cause of female infertility in approximately 30% of women and 10-25% of these are due to proximal tubal obstruction. Selective salpingography represent an approach in the diagnosis and treatment of proximal tubal abnormalities. Intralipid (IL) is a synthetic product composed of 10 % soybean oil, 1,2 % egg yolk phospholipids, 2.25 % glycerin, and water. When indicated, IL is infused 7–10 days prior to embryo transfer (ET), Rates of ongoing pregnancy and live births were higher among women who underwent hysterosalpingography with oil contrast than among women who underwent this procedure with water contrast. It is the first time that intralipid-iodine is suggested to be used for hysterosalpingography in infertile women. Keywords: Intralipid- Iodine; Hysterosalpingography; Infertility 2 Intralipid-A Magic Bullet? Tubal disease is the cause of female infertility in approximately tubes [6]. To determine whether hysterosalpingography 30% of women [1] and 10-25% of these are due to proximal (HSG) increases the conception rate and to compare the tubal obstruction [2]. Selective salpingography represent therapeutic effectiveness of oil and water soluble contrast an approach in the diagnosis and treatment of proximal media, the histories of 744 women who attended the Yale tubal abnormalities. The common indications for selective Infertility salpingography are to differentiate spasm from true Clinic in 1965-69 were reviewed. Exclusion of women obstruction [3]. In addition to that it allows clarifying findings who had been infertile less than 1 year before coming to from an equivocal hysterosalpingogram. Isthmic as well as the clinic, in whom a HSG was done outside the clinic, intramural blockages were included. The tubal obstruction and in whom there was no follow-up resulted in a study may due to amorphous materials occluding the tubal lumen, population of 460. The pregnancy rate for the study group inflammatory changes and adhesions [4]. The use of (49%) was identical to that for the larger population. The selective salpingography and fallopian tube recanalization study group was divided into women who became pregnant has revolutionized the diagnosis and treatment of infertility during their clinic attendance or within 1 year of terminating [3]. Diagnostic procedure has been used since 1980 [3]. clinic care and women who did not become pregnant in It consists on opacification of the fallopian tube directly this period. These 2 categories were then subdivided through a catheter placed in the tubal ostium. The objective according to whether a HSG was done. To determine the is to differentiate spasm from true obstruction and to clear relative effectiveness of different media, the conception it with a catheter and guide wire system. Pregnancy rates rate following HSG in the Yale Clinic, where the iodized among infertile women have been reported to increase after oil Ethiodol was used, was compared with that among 63 hysterosalpingography, but it is unclear whether the type of women who had HSG done by a private practitioner with contrast medium used (oil-based or water-soluble contrast) the water soluble dye Salpix. 221 women were in the influences this potential therapeutic effect. Ethiodol HSG group, 121 (55%) of whom conceived. Of the Dreyer et al. [5] performed a multicenter, randomized 239 Yale Clinic patients who did not have HSG, 103 (43%) trial in 27 hospitals in the Netherlands in which infertile became pregnant. Exclusion of couples with organic factors women who were undergoing hysterosalpingography were that could account for infertility resulted in a pregnancy rate randomly assigned to undergo this procedure with the use of 58% for the HSG group and 47% for the non-HSG group. of oil-based or water-based contrast. Subsequently, couples 25 (40%) of the 63 women in the Salpix group conceived, received expectant management or the women underwent but exclusion of couples with organic factors lowered the intrauterine insemination. The primary outcome was pregnancy rate to 38% in this group. The average length ongoing pregnancy within 6 months after randomization. of infertility was 0.5 years longer in the non-HSG group Outcomes were analyzed according to the intention-to-treat than in the Ethiodol HSG group, but shorter in the Salpix principle. A total of 1119 women were randomly assigned HSG group compared to the Ethiodol group. These results to hysterosalpingography with oil contrast (557 women) or suggest that Ethiodol HSG may enhance fertility. Although water contrast (562 women). A total of 220 of 554 women the oil media has been criticized on the basis that it may in the oil group (39.7%) and 161 of 554 women in the water cause granuloma formation or embolization, documented group (29.1%) had an ongoing pregnancy (rate ratio, 1.37; complications in the Yale series were rare. In contrast to 95% confidence interval [CI], 1.16 to 1.61; P<0.001), and earlier studies, unilateral nonpatency on x-ray was not 214 of 552 women in the oil group (38.8%) and 155 of 552 found to affect eventual conception (58% pregnancy rate women in the water group (28.1%) had live births (rate ratio, among women in the Ethiodol HSG group with normal tubes 1.38; 95% CI, 1.17 to 1.64; P<0.001). Rates of adverse compared with 50% in those with filling of only 1 tube) [7]. events were low and similar in the two groups. Previous studies have suggested increased fertility rates Rates of ongoing pregnancy and live births were higher following hysterosalpingography (HSG) using oil as among women who underwent hysterosalpingography compared with aqueous contrast medium.
Load more

Recommended publications
  • 204508S000lbl.Pdf
    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ____________________CONTRAINDICATIONS____________________ CLINOLIPID injection safely and effectively. See full prescribing • Known hypersensitivity to egg and soybean proteins, the lipid emulsion information for CLINOLIPID injection. and/or excipients. (4) • Severe hyperlipidemia or severe disorders of lipid metabolism. (4) CLINOLIPID (Lipid Injectable Emulsion) for intravenous use Initial U.S. Approval: 1975 ________________WARNINGS AND PRECAUTIONS_______________ • Preterm infants have poor clearance of intravenous lipid emulsion. (5.1) WARNING: DEATH IN PRETERM INFANTS • Monitor for signs or symptoms of hypersensitivity reactions. (5.2) See full prescribing information for complete boxed warning • Monitor for signs and symptoms of infection, fat overload, and refeeding • Deaths in preterm infants have been reported in literature. (5.1, complications. (5.3, 5.4, 5.5) 8.4) • Frequent clinical and laboratory determinations are necessary. (5.6) • Autopsy findings included intravascular fat accumulation in the lungs. (5.1, 8.4) __________________ADVERSE REACTIONS__________________ • Preterm and low birth weight infants have poor clearance of The most common (5%) adverse drug reactions from clinical trials were intravenous lipid emulsion and increased free fatty acid plasma nausea and vomiting, hyperlipidemia, hyperglycemia, hypoproteinemia and levels following lipid emulsion infusion. (5.1, 8.4) abnormal liver function tests. (6.1) __________________INDICATIONS AND USAGE___________________ To report SUSPECTED ADVERSE REACTIONS, contact Baxter CLINOLIPID injection is a lipid emulsion indicated in adults for parenteral Healthcare at 1-866-888-2472 or FDA at 1-800-FDA-1088 or nutrition providing a source of calories and essential fatty acids when oral or www.fda.gov/medwatch enteral nutrition is not possible, insufficient, or contraindicated.
    [Show full text]
  • Liposomes to Augment Dialysis in Preclinical Models: a Structured Review
    pharmaceutics Review Liposomes to Augment Dialysis in Preclinical Models: A Structured Review Kevin Hart 1,*, Martyn Harvey 2, Mingtan Tang 3 , Zimei Wu 3 and Grant Cave 1 1 Intensive Care Unit, Hawkes Bay District Health Board, Hastings 9014, New Zealand; [email protected] 2 Waikato Hospital Emergency Department, Waikato District Health Board, Hamilton 3240, New Zealand; [email protected] 3 Faculty of Medicine and Health Sciences, School of Pharmacy, University of Auckland, Auckland 1023, New Zealand; [email protected] (M.T.); [email protected] (Z.W.) * Correspondence: [email protected] Abstract: In recent years, a number of groups have been investigating the use of “empty” liposomes with no drug loaded as scavengers both for exogenous intoxicants and endogenous toxic molecules. Preclinical trials have demonstrated that repurposing liposomes to sequester such compounds may prove clinically useful. The use of such “empty” liposomes in the dialysate during dialysis avoids recognition by complement surveillance, allowing high doses of liposomes to be used. The “reach” of dialysis may also be increased to molecules that are not traditionally dialysable. We aim to review the current literature in this area with the aims of increasing awareness and informing further research. A structured literature search identified thirteen papers which met the inclusion criteria. Augmenting the extraction of ammonia in hepatic failure with pH-gradient liposomes with acidic centres in peritoneal dialysis is the most studied area, with work progressing toward phase one trials. Liposomes used to augment the removal of exogenous intoxicants and protein- Citation: Hart, K.; Harvey, M.; Tang, bound uraemic and hepatic toxins that accumulate in these organ failures and liposome-supported M.; Wu, Z.; Cave, G.
    [Show full text]
  • 6 Literaturverzeichnis
    6 Literaturverzeichnis 6 Literaturverzeichnis Adam, A., Lederer, E., Muramyl peptides: Immunomodulators, sleep factors and vitamins. Med. Res. Rev. 4, 111-153, 1984. Akao, T., Correlation between physicochemical characteristics of synthetic cationic am- phiphiles and their DNA transfection ability. Bull. Chem. Soc. Jpn. 64, 3677-3681, 1991. Allison, A.C., Byars, N.E., Immunological adjuvants: desirable properties and side-effects. Mol. Immunol. 28, 279-284, 1991. Alving, C.R., Verma, J.N., Rao, U., Krzych, U., Amselem, S. Green, S.M., Wassef, N.M., Liposomes containing lipid A as potent non-toxic adjuvant. Res. Immunol. 143, 197-198, 1992. Alving, C.R., Lipopolysaccharide, lipid A and liposomes containing lipid A as immuno- logic adjuvants. Immunobiology 187, 430-446, 1993. Anderson, W.F., Human gene therapy. Nature 392, 25-30, 1998. Aprile, M.A., Wardlaw, A.C.,Aluminum compounds as adjuvants for vaccines and toxoids in man: a review. Can. J. Publ. Hlth 57, 343-354, 1966. Avrameas, S., Guilbert, B., Dosage enzymoimmunologique de protéine à l'aide d'immu- noadsorbants et d'antigènes marqués aux enzymes. C. R. Acad. Sci.(Paris) 273, 2705-2707, 1971. Bally, M.B., Harvie, P., Wong, F.M.P., Kong, S., Wasan, E.K., Reimer, D.L., Biological barriers to cellular delivery of lipid-based DNA carriers. Adv. Drug Deliv. Rev. 38, 291- 315, 1999. Behr, J.P., Gene transfer with synthetic cationic amphiphiles: Prospects for Gene Therapy. Bioconj. Chem. 5, 382-389, 1994. Binnig, G., Quate, C.F., Gerber, C., Atomic force microscopy. Phys. Rev. Lett. 56, 930- 933, 1986. Biocompare.com, Auflistung kommerzieller liposomaler Transfektiosagenzien unter http://biocompare.com Birchall, J.C., Kellaway, I.W., Mills, S.N., Physico-chemical characterisation and trans- fection efficiency of lipid-based gene delivery complexes.
    [Show full text]
  • Treatment for Calcium Channel Blocker Poisoning: a Systematic Review
    Clinical Toxicology (2014), 52, 926–944 Copyright © 2014 Informa Healthcare USA, Inc. ISSN: 1556-3650 print / 1556-9519 online DOI: 10.3109/15563650.2014.965827 REVIEW ARTICLE Treatment for calcium channel blocker poisoning: A systematic review M. ST-ONGE , 1,2,3 P.-A. DUB É , 4,5,6 S. GOSSELIN ,7,8,9 C. GUIMONT , 10 J. GODWIN , 1,3 P. M. ARCHAMBAULT , 11,12,13,14 J.-M. CHAUNY , 15,16 A. J. FRENETTE , 15,17 M. DARVEAU , 18 N. LE SAGE , 10,14 J. POITRAS , 11,12 J. PROVENCHER , 19 D. N. JUURLINK , 1,20,21 and R. BLAIS 7 1 Ontario and Manitoba Poison Centre, Toronto, ON, Canada 2 Institute of Medical Science, University of Toronto, Toronto, ON, Canada 3 Department of Clinical Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada 4 Direction of Environmental Health and Toxicology, Institut national de sant é publique du Qu é bec, Qu é bec, QC, Canada 5 Centre Hospitalier Universitaire de Qu é bec, Qu é bec, QC, Canada 6 Faculty of Pharmacy, Université Laval, Qu é bec, QC, Canada 7 Centre antipoison du Qu é bec, Qu é bec, QC, Canada 8 Department of Medicine, McGill University, Montr é al, QC, Canada 9 Toxicology Consulting Service, McGill University Health Centre, Montr é al, QC, Canada 10 Centre Hospitalier Universitaire de Qu é bec, Qu é bec, QC, Canada 11 Centre de sant é et services sociaux Alphonse-Desjardins (CHAU de Lévis), L é vis, QC, Canada 12 Department of Family Medicine and Emergency Medicine, Universit é Laval, Québec, QC, Canada 13 Division de soins intensifs, Universit é Laval, Qu é bec, QC, Canada 14 Populations
    [Show full text]
  • Role of IV Lipid Emulsion Antidote
    Vet Times The website for the veterinary profession https://www.vettimes.co.uk Role of IV lipid emulsion antidote Author : Lotfi El Bahri Categories : General, Vets Date : March 28, 2016 The first animal reports suggesting an increased rate of recovery from barbiturate-induced CNS depression with lipid infusion were published in 19621. Encouraging results of animal studies, and successful use in human case reports, have demonstrated lipid emulsion has a potential role in the treatment of lipophilic molecules intoxications2. Background Image: Fotolia/Sherry Young. Lipid emulsion – also referred to as intravenous lipid emulsion (ILE), lipid resuscitation therapy, intravenous lipid emulsion rescue and intravenous fat emulsion – is known as a component of parenteral nutrition (ILE 30 per cent). It is also used as a carrier for lipid soluble drugs, such as propofol, etomidate and diazepam3,4. ILE is an injectable oil in water emulsion mixing long-chain and medium-chain triglycerides, or a combination of both, purified egg phospholipids as emulsifiers, anhydrous glycerol for the adjustment of tonicity, water for injection (with a pH of six to nine) and contains no preservatives3,4. ILE is available in concentrations ranging from 10 per cent to 30 per cent. Although purified 1 / 6 soybean oil is most commonly used as the major source of triglycerides, other sources are also used (such as olive oil and fish oil)3,4. The United States Pharmacopeia and the European Pharmacopoeia standards have established a globule size distribution limit for all lipid emulsions where the mean droplet size must be lower than 500 nanometres, and the percentage of fat larger than 5µm must be lower than 0.05 per cent5.
    [Show full text]
  • Nanoparticle System Based on Amino-Dextran As a Drug Delivery Vehicle: Immune-Stimulatory Cpg-Oligonucleotide Loading and Delivery
    pharmaceutics Article Nanoparticle System Based on Amino-Dextran as a Drug Delivery Vehicle: Immune-Stimulatory CpG-Oligonucleotide Loading and Delivery Hien V. Nguyen 1,2, Katrin Campbell 2 , Gavin F. Painter 3, Sarah L. Young 4 and Greg F. Walker 1,* 1 School of Pharmacy, University of Otago, Dunedin 9016, New Zealand; [email protected] 2 Department of Pathology, University of Otago, Dunedin 9016, New Zealand; [email protected] 3 The Ferrier Research Institute, Victoria University of Wellington, Wellington 5040, New Zealand; [email protected] 4 School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney 2006, NSW, Australia; [email protected] * Correspondence: [email protected]; Tel.: +64-3-479-7133 Received: 11 November 2020; Accepted: 25 November 2020; Published: 27 November 2020 Abstract: The aim of this study is to prepare and characterize an amino-dextran nanoparticle (aDNP) platform and investigate two loading strategies for unmethylated cytosine-phosphate-guanine (CpG) oligonucleotide. aDNP was prepared by desolvation of amino-dextran followed by the chemical crosslinking of amino groups. Size, surface charge, and surface morphology of aDNP was determined by dynamic light scattering and transmission electron microscopy. CpG was either loaded onto aDNP by adsorption (CpG-adsorbed-aDNP) or conjugated to aDNP (CpG-conjugated-aDNP). In vitro cytokine production by bone marrow-derived dendritic cells (BMDCs) was measured by flow cytometry. aDNPs size and zeta potential could be controlled to produce uniform particles in the size range of 50 to 300 nm, surface charge of 16.5 to +14 mV, and were spherical in shape.
    [Show full text]
  • Intravenous Lipid Emulsions in the Treatment of Essential Fatty Acid Deficiency: Studies in Young Pigs
    ANDERSEN ET AL. 003 1-3998/84/18 12-1 350$02.00/0 PEDIATRIC RESEARCH Vol. 18, No. 12, 1984 Copyright O 1984 International Pediatric Research Foundation, Inc. Printed in U.S.A. Intravenous Lipid Emulsions in the Treatment of Essential Fatty Acid Deficiency: Studies in Young Pigs DEAN W. ANDERSEN, L. J. FILER, JR., AND LEWIS D. STEGINK The University of Iowa, Departments of Pediatrics and Biochemistry, Iowa City, Iowa 52242 ABSTRACT. Essential fatty acid deficiency (EFAD) oc- fed fat-free diets usually fast overnight, causing triglyceride mo- curs in infants fed fat-free mixtures of glucose and amino bilization from adipose tissue to supply energy needs. Essential acids. Although infusion of lipid emulsion rapidly reverses fatty acids are released to the circulation as part of this process, clinical symptoms, little is known about effects on tissue supplying requirements. When a nutritional regimen that does fatty acids. To study this question, five groups (n = 41 not provide sufficient energy is fed, a similar process occurs. group) of neonatal pigs were studied. Three groups (I, 11, During eucaloric or hypercaloric total parenteral or enteral and V) were made EFAD by feeding diets without essential nutrition, total energy requirements are supplied by constant fatty acids (EFA) for days 5 to 33 of life. Groups 111 and infusion of glucose-amino acid mixtures in amounts equal to or IV were fed a control diet. By 33 days, animals fed the greater than energy requirements. The increased insulin levels deficient diet showed clinical symptoms and biochemical produced by such infusions decrease adipose tissue lipase activity, signs of EFAD.
    [Show full text]
  • The Relationship Between Oxytocin, Dietary Intake and Feeding A
    Frontiers in Neuroendocrinology 52 (2019) 65–78 Contents lists available at ScienceDirect Frontiers in Neuroendocrinology journal homepage: www.elsevier.com/locate/yfrne The relationship between oxytocin, dietary intake and feeding: A systematic review and meta-analysis of studies in mice and rats T Janelle A. Skinnera,b, Erin J. Campbellc,d, Christopher V. Dayase, Manohar L. Garge, ⁎ Tracy L. Burrowsa,b, a Nutrition and Dietetics, School of Health Sciences, Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW 2308, Australia b Priority Research Centre for Physical Activity and Nutrition, University of Newcastle, Callaghan, NSW 2308, Australia c The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria 3052, Australia d Florey Department of Neuroscience and Mental Health, University of Melbourne, Victoria 3010, Australia e School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW 2308, Australia ARTICLE INFO ABSTRACT Keywords: The neuropeptide oxytocin has been associated with food intake and feeding behaviour. This systematic review Dietary intake aimed to investigate the impact of oxytocin on dietary intake and feeding behaviour in rodent studies. Six Feeding behaviour electronic databases were searched to identify published studies to April 2018. Preclinical studies in mice and Oxytocin rats were included if they reported: (1) a dietary measure (i.e. food or nutrient and/or behaviour (2) an oxytocin Addiction measure, and (3) relationship between the two measures. A total of 75 articles (n = 246 experiments) were Mice included, and study quality appraised. The majority of studies were carried out in males (87%). The top three Rats oxytocin outcomes assessed were: exogenous oxytocin administration (n = 126), oxytocin-receptor antagonist administration (n = 46) and oxytocin gene deletion (n = 29).
    [Show full text]
  • Evidence-Based Recommendations on the Use of Intravenous Lipid Emulsion Therapy in Poisoning
    Clinical Toxicology ISSN: 1556-3650 (Print) 1556-9519 (Online) Journal homepage: http://www.tandfonline.com/loi/ictx20 Evidence-based recommendations on the use of intravenous lipid emulsion therapy in poisoning Sophie Gosselin, Lotte C. G. Hoegberg, Robert. S. Hoffman, Andis Graudins, Christine M. Stork, Simon H. L. Thomas, Samuel J. Stellpflug, Bryan D. Hayes, Michael Levine, Martin Morris, Andrea Nesbitt-Miller, Alexis F. Turgeon, Benoit Bailey, Diane P. Calello, Ryan Chuang, Theodore C. Bania, Bruno Mégarbane, Ashish Bhalla & Valéry Lavergne To cite this article: Sophie Gosselin, Lotte C. G. Hoegberg, Robert. S. Hoffman, Andis Graudins, Christine M. Stork, Simon H. L. Thomas, Samuel J. Stellpflug, Bryan D. Hayes, Michael Levine, Martin Morris, Andrea Nesbitt-Miller, Alexis F. Turgeon, Benoit Bailey, Diane P. Calello, Ryan Chuang, Theodore C. Bania, Bruno Mégarbane, Ashish Bhalla & Valéry Lavergne (2016) Evidence-based recommendations on the use of intravenous lipid emulsion therapy in poisoning, Clinical Toxicology, 54:10, 899-923, DOI: 10.1080/15563650.2016.1214275 To link to this article: http://dx.doi.org/10.1080/15563650.2016.1214275 Published online: 08 Sep 2016. Submit your article to this journal Article views: 1732 View related articles View Crossmark data Citing articles: 1 View citing articles Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ictx20 Download by: [Maine Medical Center] Date: 16 January 2017, At: 06:53 CLINICAL TOXICOLOGY, 2016 VOL. 54, NO. 10, 899–923 http://dx.doi.org/10.1080/15563650.2016.1214275 REVIEW Evidence-based recommendations on the use of intravenous lipid emulsion à therapy in poisoning Sophie Gosselina,b,c , Lotte C.
    [Show full text]
  • Pileptic Fosphenytoin
    PACKAGE LEAFLET: INFORMATION FOR THE PATIENT TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion Read all of this leaflet carefully before you will be administered this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or nurse. • If you get any side effect, talk to your doctor or nurse. This includes any side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is and what it is used for 2. What you need to know before TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is administered 3. How TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion will be used 4. Possible side effects 5. How TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is stored 6. Contents of the pack and other information 1. What TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is and what it is used for TRIOMEL is an emulsion for infusion. It is presented in a bag with 3 chambers. One chamber contains a glucose solution, the second one contains a lipid emulsion and the third one contains an amino acid solution. TRIOMEL is used to provide nutrition to adults and children greater than 2 years of age by a tube into a vein when normal feeding by mouth is not suitable. TRIOMEL must only be used under medical supervision.
    [Show full text]
  • Summary of Product Characteristics 1. Name Of
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Numeta G19E emulsion for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION This medicinal product is presented in the form of a three chamber bag. Each bag contains a sterile non-pyrogenic combination of a glucose solution, a paediatric amino acids solution, with electrolytes, and a lipid emulsion, as described below. Container size 50% glucose solution 5.9% amino acids solution 12.5% lipid emulsion with electrolytes 1000 mL 383 mL 392 mL 225 mL If lipid administration is undesirable, the design of the bag allows the possibility to activate only the peel seal between the amino acids/electrolytes and glucose chambers, leaving the peel seal between the amino acids and lipid chambers intact. The content of the bag can subsequently be infused with or without lipids. The composition of the drug product after mixing of the two (amino acids and glucose 2 chamber bag, 775 mL solution) or three (amino acids, glucose and lipid 3 chamber bag, 1000 mL emulsion) chambers are provided in the following table. Page 1 of 28 Composition Active Substance Activated 2CB Activated 3CB (775 mL) (1000 mL) Amino Acid Chamber Alanine 1.83 g 1.83 g Arginine 1.92 g 1.92 g Aspartic acid 1.37 g 1.37 g Cysteine 0.43 g 0.43 g Glutamic acid 2.29 g 2.29 g Glycine 0.91 g 0.91 g Histidine 0.87 g 0.87 g Isoleucine 1.53 g 1.53 g Leucine 2.29 g 2.29 g Lysine monohydrate 2.82 g 2.82 g (equivalent to Lysine) (2.51 g) (2.51 g) Methionine 0.55 g 0.55 g Ornithine hydrochloride 0.73 g 0.73 g (equivalent to Ornithine)
    [Show full text]
  • Intralipid®10%, 20% and 30%, Intravenous Infusion for Injection
    NEW ZEALAND DATA SHEET 1 PRODUCT MEDICINE Intralipid®10%, 20% and 30%, intravenous infusion for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Soya oil is a mixture of triglycerides, i.e. triacylglycerols. The triglycerides, triacylglycerols, are fatty acid triesters of glycerol (propane-1, 2, 3-triol). The main fatty acids are linoleic acid (C18:2), oleic acid (C18:1) and palmitic acid (C16:0). The number of double bonds in the different fatty acids can vary from zero (saturated) to three (unsaturated). As with most vegetable oils, the saturated acids are preferably esterified in sn-1 and sn-3 position. The molecular structure is well known from general literature on lipid chemistry. Soya oil structural formula. General structure of a triglyceride, R1, R2 and R3 are long-chain alkyl groups. Molecular weight: 871 g/mol (typical mean value, the molecular weight depends on the fatty acid pattern of the triglyceride). CAS number 8001-22-7. Sterile fat emulsions for intravenous infusion containing: Content Intralipid 10% Intralipid 20% Intralipid 30% per 1000 mL Active Soya oil 100 g 200 g 300 g Osmolality (mOsmol/kg water) 300 350 310 Energy Content kcal (kJ) 1100 (4600) 2000 (8400) 3000 (12600) For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Intravenous infusion for Injection. A milky white liquid. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Part of the intravenous diet in all parenteral nutrition indications including: 1) Preoperative and postoperative nutritional disturbances where
    [Show full text]